Forward Citations = 337

Loading Chart...

2 inventors (with patents filed for the assignee):

Peter J Andrulis, Jr (6 out of 8 patents)

Murray W Drulak (4 out of 4 patents)

6 patents: Sort by Forward Citations

1. 6140346 - Treatment of cancer with thalidomide alone or in combination with other (2000-10-31),

2. 5731325 - Treatment of melanomas with thalidomide alone or in combination with (1998-03-24),

3. 5654312 - Treatment of inflammatory and/or autoimmune dermatoses with thalidomide (1997-08-05),

4. 5643915 - Treatment of ischemia/reperfusion injury with thalidomide alone or in (1997-07-01),

5. 5434170 - Method for treating neurocognitive disorders (1995-07-18),

6. 5405855 - Treatment of insulin resistant diabetes with thalidomine (1995-04-11),

Andrulis Pharmaceuticals Corp. is a biopharmaceutical company specializing in the research and development of novel treatments for cancer. With a focus on precision medicine, Andrulis Pharma is dedicated to delivering personalized therapies that target specific genetic mutations in tumors. The company's innovative approach to drug discovery and development has led to the advancement of several promising drug candidates in various stages of clinical trials.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

6 Patents

#44 in Bethesda, MD

#633 in Maryland

#44,949 in US

Bethesda, MD, United States of America

Andrulis Pharmaceuticals Corp.

Forward Citations = 337

2 inventors:

Peter J Andrulis, Jr (6 out of 8 patents)

Murray W Drulak (4 out of 4 patents)

Please report any incorrect information to [email protected]